Korean Regulatory Post Marketing Surveillance for Somavert

Pfizer11 enrolled

Overview

Non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)

Study Type

OBSERVATIONAL

Enrollment

Conditions

Acromegaly

Interventions

SomavertDRUG

As provided in real world practice

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: All patients who have been prescribed as per local label and investigators' judgement under the setting of routine practice in Korea who are eligible. Exclusion Criteria: Patients who are contraindicated for Somavert

Locations (1)

Pfizer

Seoul, South Korea

Outcomes

Primary Outcomes

Number of participants who experience adverse events

Time frame: Baseline through 28 days after last dose (approximately 52 weeks)

Secondary Outcomes

Number of participants who experience Clinical Improvement as assessed by investigator

Time frame: Baseline through approximately 52 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.